biotech · Atopic Dermatitis · Moderate to Severe Atopic Dermatitis · KYMR
Kymera Therapeutics
Kymera Therapeutics is a biotech organization headquartered in Watertown, USA. It trades on NYSE under ticker KYMR. Primary therapeutic focus areas include Atopic Dermatitis, Moderate to Severe Atopic Dermatitis, Uncontr
500 North Beacon Street, 4th Floor, Watertown, MA 02472, US HQ
2016 Founded
289 Employees
Public company Type
KYMR · NYSE Ticker
Company details
- Status
- Public
- HQ
- 500 North Beacon Street, 4th Floor, Watertown, MA 02472, US
- Founded
- 2016
- Employees
- 289
- Programs
- 12
- Drugs
- 6
- Patents
- 29
KT-621
Phase 2 · small molecule · Atopic Dermatitis
KT-621 for Atopic Dermatitis is a Phase 2 program (small_molecule) at Kymera Therapeutics with 2 ClinicalTrials.gov record(s).
Internal code KT621-AD-102
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Kymera Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Atopic Dermatitis
- Status
- active
- Trials
- 2